A randomized phase-II study of BB-10010 (macrophage inflammatory protein-1α) in patients with advanced breast cancer receiving 5- fluorouracil, adriamycin, and cyclophosphamide chemotherapy

Blood

Volumn 92, Issue 5, 1998, Pages 1532-1540

  Clemons, Mark J ^b   Marshall, Ernest ^b   Dürig, Jan ^b   Watanabe, Ken ^b   Howell, Anthony ^a   Miles, David ^b   Earl, Helena ^b   Kiernan, Julie ^b   Griffiths, Audrey ^b   Towlson, K ^b   DeTakats, P ^b   Testa, Nydia G ^b   Dougal, Mark ^b   Hunter, Michael G ^b   Michael Wood, L ^b   Czaplewski, Lloyd G ^b   Millar, Andrew ^b   Dexter, T Michael ^b   Lord, Brian I ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HEMOGLOBIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE;

EID: 0032170455     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1532     Document Type: Article

References (34)

1. Carmo-Pereira J, Costa, FO, Henriques E, Godinho F, Cantinho-Lopes MG, Sales-Luis A, Rubens RD: A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56:471, 1987
2. Bronchud MH, Howell, A, Crowther D, Hopwood P, Souza L, Dexter TM: The use of granulocyte colony stimulating factor to increase the intensity of treatment with doxorubicin in breast and ovarian cancer. Br J Cancer 60:11, 1989
3. Lorhrmann H-P, Schreml W, Lang M, Betzler M, Fliedner TM, Hiempel H: Changes of granulopoiesis during and after adjuvant chemotherapy of Breast cancer. Br J Haematol 40:369, 1978
4. Le Chevalier T: Dose optimisation and intensification of cytotoxics in solid tumours supported by haemopoietic growth factors. Eur J Cancer 30A:410, 1994
5. Van Hoef ME, Baumann I, Lange C, Luft T, De Wynter E, Ranson M, Morgenstern G, Yvers A, Dexter TM, Testa NG, Howell A: Dose escalating induction chemotherapy supported by lenogastrim preceeding high dose consolidation chemotherapy for advanced breast cancer. Selection of the optimal regimen to induce maximal tumour response and investigation of the optimal time to collect peripheral blood progenitor cells for bone marrow rescue. Ann Oncol 5:217, 1994
6. Baumann I, van Hoeff M, Swindell R, Lange C, de Wynter E, Howell A, Dexter TM, Testa NG: The peak numbers of colony forming cells and of CD34 cells released into the peripheral blood after G-CSF with or without chemotherapy may not be correlated with the capacity of harvested blood cells to repopulate bone marrow. Ann Oncol 7:1051, 1995
7. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585, 1980
8. Hryniuk WM: The importance of dose intensity in the outcome of chemotherapy, in De Vita VT, Hellman S, Rosenberg SA (eds):Important Advances in Oncology. Philadelphia, PA, Lippincott, 1988, p 121
9. Gurney H, Dodwell D, Thatcher N, Tattersall MH: Escalating drug delivery in cancer chemotherapy: A review of concepts and practice. Parts I and II. Ann Oncol 4:23 (Part I) and 103 (Part II), 1993
10. Pettengel R, Woll P, Thatcher N, Dexter TM, Testa N: Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of haemopoietic progenitors in whole blood. J Clin Oncol 13:148, 1995
11. Woll P, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N: Can cytotoxic dose intensity be increased by using granulocyte colony stimulating factor? A randomised controlled trial of lenogastrim in small cell lung cancer. J Clin Oncol 3:652, 1995
12. Hornung RL, Longo DL: Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high dose cyclophosphamide therapy. Blood 80:77,1992
13. Guigon M, Enouf J, Frindel E: Effects of CFU-S inhibitors on murine bone marrow during Ara C treatment I. Effects on stem cells. Leuk Res 4:385, 1980
14. Guigon M, Bonnet D, Lemoine F, Kobari L, Parmentier C, Mary JY, Najman A: Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Exp Hematol 18:1112, 1990
15. Lord BJ, Dexter TM, Clements JM, Hunter MG, Gearing AJH: Macrophage inflammatory protein-1α protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood 79:2605, 1992
16. Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T, Kerr DT, Wolpe SD, Pragnell IB: Demonstration of stem cell inhibition and myeloproliferative effects of SCI/rhMIP-1α in vivo. Blood 79:2221, 1992
17. Migdalska A, Molineux G, Demunyck H, Evans GS, Ruscetti F, Dexter TM: Growth inhibitory effects of transforming growth factor β in vivo. Growth Factors 4:239, 1991
18. Paukovits WR, Moser M-H, Paukovits JB: Pre-CFU-S quiescence and stem cell exhaustion after cytostatic drug treatment. Protective effects of the inhibitory peptide pGlu-Glu-Asp-Gys-Lys (pEEDCK). Blood 87:1755, 1993
19. Paukovits WR, Moser M-H, Binder KA, Paukovits JB: Protection from arabinofuranosylcytosine and n-mustard-induced myelotoxicity using hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys monomer and dimer. Blood 77:1313, 1991
20. Molineux G, Migdalaska A, Haley J, Evans GS, Dexter TM: Total marrow failure induced by pegylated stem cell factor administered before 5-fluorouracil. Blood 83:3491, 1994
21. Sonis ST, Linquist L, Van Vugt A, Stewart AA, Stam K, Qu G-Y, Iwata KK, Hayley JD: Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor-beta 3. Cancer Res 54:1135, 1994
22. Wolpe SD, Cerami A: Macrophage inflammatory proteins 1 and 2: Members of a novel superfamily of cytokines. FASEB J 3:2565, 1989
23. Lord BI: MIP1α increases the self renewal capacity of the haemopoietic spleen colony forming cells following hydroxyurea treatment in vivo. Growth Factors 12:145, 1995
24. Hunter MG, Bawden L, Brotherton D, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Gearing AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM, Lewis PJ: BB-10010: An active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Blood 12:4400, 1995
25. Lord BI, Marshall E, Woolford LB, Hunter MG: BB-10010/MIP-1α in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation. Br J Cancer 74:1017, 1996
26. Marshall E, Woolford LB, Lord BI: Continuous infusion of macrophage inflammatory protein MIP-1α enhances leucocyte recovery and progenitor cell mobilisation after cylophosphamide. Br J Cancer 75:1715, 1997
27. Marshall E, Powles R, Millar A, Hunter MG, Edwards M, Wood LM, Testa N, Dexter TM, Lord BI, Howell AH: Clinical effects of human MIP-1α (LD78) administration to humans: A phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. Eur J Cancer (in press)
28. Couthino LH, Gilleece MH, de Wynter EA, Will A, Testa NG: Clonal and long term cultures using human bone marrow, in Testa NG, Molineux G (eds): Haemopoiesis, A Practical Approach. New York, NY, Oxford, 1993, p 75
29. De Wynter EA, Coutinho LH, Pei X, Marsh SCW, Hows J, Luft T, Testa NG: Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems. Stem Cells 13:524, 1995
30. Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, Christiansen N, Reece D, Ericson S, Stephan M, Kovalsky M, Hawkins K, Rasmussen H, Devos A, Herzig GP: A randomized phase II study of BB-10010: A variant of human macrophage inflammatory protein-1α for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer. Br J Haematol 99:388, 1997
31. Williams SL, Addison IE, Mallopour E, Czaplewski LG, Linch DC, Roberts PJ: The effects of human macrophage inflammatory protein-1α and its genetically modified variant, B-10010, on phagocyte function. Cytokines Mol Therap 3:41, 1997
32. Lord BI, Woolford LB, Wood LM, Gaplewski LG, McCourt M, Hunter MG, Edwards RM: Mobilization of early hematopoietic progenitor cells with BB-10010: A genetically engineered variant of human macrophage inflammatory proetin-1α, Blood 85:3412, 1995
33. Broxmeyer HE, Hague NL, Sledge GW Jr, Ramussen H, Gordon MS: Suppression of marrow and mobilization of blood myeloid progenitors in vivo by BB-10010. A genetically engineered variant of human macrophage, inflammatory protein (MIP-1α) in a phase-1 clinical trial in patients with relapsed/refractory breast cancer. Blood 86:12a, 1995 (suppl 1, abstr 37)
34. Baumann I, Swindell R, van Hoeff MEHM, Dexter TM, de Wynter E, Lange C, Luft T, Howell A, Testa NG: Mobilization kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. Ann Oncol 7:1951, 1996